Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Sarah R Verhoeff; Suzanne C van Es; Eline Boon; Erik van Helden; Lindsay Angus; Sjoerd G Elias; Sjoukje F Oosting; Erik H Aarntzen; Adrienne H Brouwers; Thomas C Kwee; Sandra Heskamp; Otto S Hoekstra; Henk Verheul; Astrid A M van der Veldt; Elisabeth G E de Vries; Otto C Boerman; Winette T A van der Graaf; Wim J G Oyen; Carla M L van Herpen

doi:10.1007/s00259-019-04358-9

Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Sarah R Verhoeff, Suzanne C van Es, Eline Boon, Erik van Helden, Lindsay Angus, Sjoerd G Elias, Sjoukje F Oosting, Erik H Aarntzen, Adrienne H Brouwers, Thomas C Kwee, Sandra Heskamp, Otto S Hoekstra, Henk Verheul, Astrid A M van der Veldt, Elisabeth G E de Vries, Otto C Boerman, Winette T A van der Graaf, Wim J G Oyen, Carla M L van Herpen^*

^*Corresponding author for this work

Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Research output: Contribution to journal › Article › Academic › peer-review

78 Citations (Scopus)

223 Downloads (Pure)

Abstract

PURPOSE: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.

METHODS: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax) were measured.

RESULTS: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87-94) versus 56% (95%CI: 50-62, p = 0.001), respectively, and more than CT and [18F]FDG-PET/CT combined (84% (95%CI:79-88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.

CONCLUSIONS: The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.

Original language	English
Pages (from-to)	1931-1939
Number of pages	9
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	46
Issue number	9
Early online date	6-Jun-2019
DOIs	https://doi.org/10.1007/s00259-019-04358-9
Publication status	Published - Aug-2019

Keywords

CAIX
Clear cell renal cell carcinoma
FDG
Girentuximab
Imaging
PET
CARBONIC-ANHYDRASE-IX
INDEPENDENT PREDICTOR
SURVIVAL
IMPACT

Access to Document

10.1007/s00259-019-04358-9Licence: CC BY

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaFinal publisher's version, 2.87 MBLicence: CC BY

Handle.net

Persistent link

Cite this

Verhoeff, S. R., van Es, S. C., Boon, E., van Helden, E., Angus, L., Elias, S. G., Oosting, S. F., Aarntzen, E. H., Brouwers, A. H., Kwee, T. C., Heskamp, S., Hoekstra, O. S., Verheul, H., van der Veldt, A. A. M., de Vries, E. G. E., Boerman, O. C., van der Graaf, W. T. A., Oyen, W. J. G., & van Herpen, C. M. L. (2019). Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1931-1939. https://doi.org/10.1007/s00259-019-04358-9

@article{cf169f88d2c748b99e8762ee181ee431,

title = "Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma",

abstract = "PURPOSE: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.METHODS: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax) were measured.RESULTS: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87-94) versus 56% (95%CI: 50-62, p = 0.001), respectively, and more than CT and [18F]FDG-PET/CT combined (84% (95%CI:79-88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.CONCLUSIONS: The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.",

keywords = "CAIX, Clear cell renal cell carcinoma, FDG, Girentuximab, Imaging, PET, CARBONIC-ANHYDRASE-IX, INDEPENDENT PREDICTOR, SURVIVAL, IMPACT",

author = "Verhoeff, {Sarah R} and {van Es}, {Suzanne C} and Eline Boon and {van Helden}, Erik and Lindsay Angus and Elias, {Sjoerd G} and Oosting, {Sjoukje F} and Aarntzen, {Erik H} and Brouwers, {Adrienne H} and Kwee, {Thomas C} and Sandra Heskamp and Hoekstra, {Otto S} and Henk Verheul and {van der Veldt}, {Astrid A M} and {de Vries}, {Elisabeth G E} and Boerman, {Otto C} and {van der Graaf}, {Winette T A} and Oyen, {Wim J G} and {van Herpen}, {Carla M L}",

year = "2019",

month = aug,

doi = "10.1007/s00259-019-04358-9",

language = "English",

volume = "46",

pages = "1931--1939",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "9",

}

Verhoeff, SR, van Es, SC, Boon, E, van Helden, E, Angus, L, Elias, SG, Oosting, SF, Aarntzen, EH, Brouwers, AH , Kwee, TC, Heskamp, S, Hoekstra, OS, Verheul, H, van der Veldt, AAM, de Vries, EGE, Boerman, OC, van der Graaf, WTA, Oyen, WJG & van Herpen, CML 2019, 'Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma', European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 9, pp. 1931-1939. https://doi.org/10.1007/s00259-019-04358-9

Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. / Verhoeff, Sarah R; van Es, Suzanne C; Boon, Eline et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, No. 9, 08.2019, p. 1931-1939.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

AU - Verhoeff, Sarah R

AU - van Es, Suzanne C

AU - Boon, Eline

AU - van Helden, Erik

AU - Angus, Lindsay

AU - Elias, Sjoerd G

AU - Oosting, Sjoukje F

AU - Aarntzen, Erik H

AU - Brouwers, Adrienne H

AU - Kwee, Thomas C

AU - Heskamp, Sandra

AU - Hoekstra, Otto S

AU - Verheul, Henk

AU - van der Veldt, Astrid A M

AU - de Vries, Elisabeth G E

AU - Boerman, Otto C

AU - van der Graaf, Winette T A

AU - Oyen, Wim J G

AU - van Herpen, Carla M L

PY - 2019/8

Y1 - 2019/8

N2 - PURPOSE: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.METHODS: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax) were measured.RESULTS: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87-94) versus 56% (95%CI: 50-62, p = 0.001), respectively, and more than CT and [18F]FDG-PET/CT combined (84% (95%CI:79-88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.CONCLUSIONS: The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.

AB - PURPOSE: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.METHODS: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax) were measured.RESULTS: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87-94) versus 56% (95%CI: 50-62, p = 0.001), respectively, and more than CT and [18F]FDG-PET/CT combined (84% (95%CI:79-88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.CONCLUSIONS: The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.

KW - CAIX

KW - Clear cell renal cell carcinoma

KW - FDG

KW - Girentuximab

KW - Imaging

KW - PET

KW - CARBONIC-ANHYDRASE-IX

KW - INDEPENDENT PREDICTOR

KW - SURVIVAL

KW - IMPACT

U2 - 10.1007/s00259-019-04358-9

DO - 10.1007/s00259-019-04358-9

M3 - Article

C2 - 31172212

SN - 1619-7070

VL - 46

SP - 1931

EP - 1939

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 9

ER -

Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this